SUMMARY Treatment with nebulised salbutamol or a mixture of salbutamol and ipratropium was given to 138 children. Length of hospital stay and number of nebulised doses required did not differ. In severe asthma response was greater with salbutamol alone. In mild asthma response was greater with combined treatment.
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Ipratropium bromide is an effective bronchodilator in children.L3 There are potential advantages in combining it with a beta adrenergic agent in treating asthma.2 We aimed to discover whether the addition of ipratropium to treatment with salbutamol would lead to a therapeutic response greater than that attainable with salbutamol alone.
Patients
All patients admitted to our hospital because of asthma between October 1984 and March 1985 were studied. There were 138 children, 95 boys and 43 girls. Their ages ranged from 11 months to 15 years, with a mean of 5-0 years. Thirteen were aged under 18 months. One hundred and five (76%) had had one or more previous admissions for asthma.
Methods
The children were randomly allocated to a salbutamol or a combined treatment group. The former received 5 mg salbutamol and the latter 5 mg salbutamol mixed with 0-25 mg ipratropium in each nebuliser. Nebuliser solutions were of equal tonicity and were administered double blind.
There were 70 patients in the salbutamol group and 68 in the combined treatment group. Standardised admission sheets were used, which incorporated a score of clinical severity (scale: 0-10). The mean admission scores in each group were almost identical (4.69 and 4.52). The age and sex distribution were similar, as were the past history, family history, parental smoking history, and drugs used before admission.
Nebulisers were given within set limits at the discretion of the nursing staff. Steroids were given to children not responding satisfactorily to nebulised treatment, and intravenous aminophylline was given to children in severe respiratory_distress.
In those old enough to produce accurate readings peak expiratory flow rates were measured immediately before and 20 minutes after treatment (except at night). Percentage changes in the peak expiratory flow rate were stratified so that responses were compared at similar degrees of severity. All statistics were analysed using the Wilcoxon rank sum method for unpaired data.
Results
Mean length of hospital stay and number of doses of nebulised medicine required were similar in each group (Table 1) . Thirty five patients receiving Only 39 patients (28 boys and 11 girls) were able to provide reproducible measurements of peak expiratory flow rates (17 salbutamol, 22 combined treatment). As gauged by the initial rate severity was similar in the two groups. The median length of hospital stay was three days in those receiving salbutamol and four days in those receiving combined treatment. The median values for the number of nebulised doses received per patient were 10 and 12. These differences were not significant.
Airway obstruction before each nebuliser dose was classified as severe, moderate, or mild according to the percentage reduction in values of peak expiratory flow rate (<50%, 50%-74%, >75%), and mean peak expiratory flow rate responses were compared within these strata. The 23 children who initially had severe airways obstruction were evenly distributed between the treatment groups. Severe airways obstruction responded significantly better to salbutamol alone (p=0007), whereas mild airways obstruction responded better to combined treatment (p=0.033); moderate airways obstruction showed little difference in response to either treatment ( Table 2 ). The trend for severe airways obstruction to respond better to salbutamol alone was not seen in the 14 children whose parents were smokers.
Discussion
No differences have been shown in the length of hospital stay or number of nebuliser doses required in children receiving nebulised salbutamol or combined salbutamol and ipratropium. In those children able to provide measurements of peak expiratory flow rate differences became apparent in that those with severe airways obstruction responded less well initally to combined treatment.
Inhaled anticholinergic agents have previously been found to be less effective during acute exacerbations of asthma than in the same patients during remission.4 This may reflect the decreased relative contribution of vagal tone to airway resistance during exacerbations of asthma. Our study suggests, however, that in severe asthma ipratropium may antagonise the action of salbutamol.
Ipratropium preferentially dilatates larger airways, and this might alter the intraluminal pressure gradient during forced expiration, resulting in earlier closure of small airways. An effect on mucus clearance cannot be excluded; ipratropium has been shown not to imTpair mucociliary clearance in adults with bronchitis, but this finding cannot be extrapolated to the small airways and viscid mucus of young asthmatic patients. Altounyan postulated a delayed effect on membrane permeability to account for a similar variation in the effect of anticholinergic agents on smooth muscle tone in vitro, the effect varying with local concentrations of histamine. 4 Whatever the explanation, we cannot recommend the addition of ipratropium to treatment regimens in acute severe childhood asthma. 
